BioCryst Pharmaceuticals, Inc.
BCRX
$9.81
$0.657.10%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 406.56M | 159.40M | 163.35M | 145.53M | 131.53M |
| Total Other Revenue | -- | -- | -- | -- | 7.35M |
| Total Revenue | 406.56M | 159.40M | 163.35M | 145.53M | 131.53M |
| Cost of Revenue | 46.12M | 46.79M | 46.18M | 41.84M | 54.33M |
| Gross Profit | 360.44M | 112.61M | 117.17M | 103.70M | 77.20M |
| SG&A Expenses | 93.74M | 83.01M | 87.38M | 82.47M | 80.44M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 139.86M | 129.80M | 133.57M | 124.31M | 134.78M |
| Operating Income | 266.70M | 29.59M | 29.79M | 21.23M | -3.24M |
| Income Before Tax | 248.02M | 12.13M | 6.49M | 758.00K | -25.99M |
| Income Tax Expenses | 2.17M | -769.00K | 1.40M | 726.00K | 804.00K |
| Earnings from Continuing Operations | 245.85M | 12.90M | 5.09M | 32.00K | -26.80M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 245.85M | 12.90M | 5.09M | 32.00K | -26.80M |
| EBIT | 266.70M | 29.59M | 29.79M | 21.23M | -3.24M |
| EBITDA | 267.09M | 29.93M | 30.12M | 21.56M | -2.94M |
| EPS Basic | 1.17 | 0.06 | 0.02 | 0.00 | -0.13 |
| Normalized Basic EPS | 0.78 | 0.04 | 0.03 | 0.00 | -0.07 |
| EPS Diluted | 1.13 | 0.06 | 0.02 | 0.00 | -0.13 |
| Normalized Diluted EPS | 0.75 | 0.04 | 0.03 | 0.00 | -0.07 |
| Average Basic Shares Outstanding | 210.97M | 210.18M | 209.52M | 208.88M | 207.38M |
| Average Diluted Shares Outstanding | 219.26M | 219.89M | 219.89M | 215.26M | 207.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |